The ACS’s mission-driven venture capital fund
Investing in for-profit companies developing novel cancer-focused treatments
Fighting for a world without cancer
Become a Donor
Our vision is to defeat cancer and advance health equity for ALL communities through patient-centric social innovation and intentional, mission-aligned impact investing.
BrightEdge exists to accelerate the American Cancer Society's goal to reduce cancer mortality, end pain and suffering, and advance health equity
Investing for science, social impact, and sustainability
BrightEdge invests invests in entrepreneurial early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies to bring innovative solutions to market.
Fighting for a World Without Cancer
BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to accelerate the commercialization of the breadth of solutions needed to target cancer from all perspectives.
American Cancer Society’s VC arm partners with Third Rock on oncology companies
Cancer startups aren’t exactly underfunded — as a disease area, oncology has commanded investors’ attention for the last decade. But the American Cancer Society sees gaps.
Third Rock Ventures Teams Up With American Cancer Society’s Venture Fund
The biotech venture firm will bring the society’s BrightEdge venture arm into cancer startup deals
BrightEdge Annual Report 2021
In 2021, BrightEdge reemerged during the darkness of the COVID-19 pandemic with resolve and focus to pave new paths for the American Cancer Society (ACS), for healthcare innovation, and for people with cancer and their caregivers.
See All News